Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of ASC40 + bevacizumab versus placebo + bevacizumab in recurrent glioblastoma
CTR20212830Phase 3Terminated
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of denifanstat, bevacizumab in glioblastoma (GBM), sponsored by Ascletis Pharma Inc.. Started Jan 2022; status: terminated.
02
Drugs
denifanstatbevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20212830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212830.